Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug

Stock Track

02/10

SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.

The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.

Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1163060577"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163060577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163060577?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163060577","market":"sg","top_or_hot":-1,"title":"Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug","media":"Stock Track","content":"<p>SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.</p><p>The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.</p><p>Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-10 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.</p><p>The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.</p><p>Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"","article_id":"1163060577","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163060577","pubTimestamp":1770691244,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.The company announced the completion of patient enrollment for a Phase III...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股赛道|中国生物制药完成乳腺癌药物III期试验入组盘中大涨5.00%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SINO BIOPHARM's stock price surged 5.00% during intraday trading on Tuesday, driven by positive clinical development news.The company announced the completion of patient enrollment for a Phase III clinical trial of its investigational drug TQB2102, a HER2-targeting bispecific antibody-drug conjugate (ADC) for HER2-low recurrent or metastatic breast cancer. This milestone represents significant progress in the drug's development pathway.Previous Phase Ib clinical results presented at the 2025 American Society of Clinical Oncology annual meeting showed promising efficacy, with an objective response rate of 53.4% in heavily pre-treated patients. The drug's innovative design aims to enhance tumor selectivity and therapeutic effectiveness while managing safety concerns.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}